Please ensure Javascript is enabled for purposes of website accessibility

The Best COVID Vaccine Stock That No One Is Talking About

By Daniel Foelber - Feb 17, 2021 at 7:05AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Healthcare investments are paying off for this dividend stock.

United Parcel Service (UPS 1.60%) just had its best year ever. The company was one of the few industrial stocks to post record-high revenue and adjusted operating income during what was otherwise a period of slowing economic growth.

UPS benefited from a surge in package delivery volumes as the pandemic shuttered brick-and-mortar stores -- sparking a surge in online shopping and selling. But higher revenue is just the headline story. Behind the scenes, the company's investments in healthcare and e-commerce paid off big in 2020, and should play a leading role in its growth for years to come.

Here's how UPS was able to capitalize on last year's trends, and why it's the best COVID-19 vaccine stock that no one is talking about.

A medical professional inserts a hypodermic needle into a vial labeled COVID-19 Vaccine.

Image source: Getty Images.

Ramping up vaccine deliveries

UPS has been in the healthcare logistics business for more than 15 years, making it the ideal transportation company to ship millions of COVID-19 vaccine doses. During its fourth-quarter conference call, CEO Carol Tome noted that UPS has delivered an astounding 36.5 million vaccines from manufacturers to dosing locations at service levels of 99.99%. Along with automotive, its healthcare business delivered single-digit business-to-business (B2B) growth in what was otherwise a challenging year for B2B sales. Healthcare contributed to a 26% year-over-year increase in fourth-quarter supply chain and freight operating profit.

The company's involvement with vaccine distribution is no accident. In fact, UPS anticipated its key role as a major distributor as early as the second quarter. In the third quarter, Tome said the following about UPS Healthcare and the pandemic:

[The] healthcare team is supporting clinical trials across all stages for COVID-19 vaccines. Early involvement gives us valuable data and insights to design commercial distribution plans and manage the logistics for these complex products. We have a great opportunity and, frankly, a great responsibility to serve the world when a COVID-19 vaccine becomes available. When that time comes, our global network, cold chain solutions, and our people will be ready.

Tome was right: UPS was ready. On Dec. 12, the company announced it was distributing the Pfizer/BioNTech vaccine according to plans received by Operation Warp Speed and officials from the Centers for Disease Control and Prevention. (Founded on May 15, 2020, Operation Warp Speed is a partnership between the U.S. government and the private sector to accelerate vaccine development and distribution.) On Dec. 18, UPS partnered with McKesson, a medical supply distributor, to deliver Moderna's vaccine. With vaccine distribution still in its infancy, investors should pay attention to UPS' involvement in the coming months to see how that translates to its top- and bottom-line results.

Vaccine growth trajectory

One of the best ways to gauge the effectiveness of UPS's vaccine delivery is through its logistics figures. UPS doesn't report its healthcare results individually. Instead, these results are folded into logistics under supply chain and freight. However, in the fourth quarter, the company did report that healthcare had its best top and bottom-line growth in company history. And UPS has attributed big spikes in logistics revenue and spending to healthcare. 

It's also worth keeping track of UPS' deliveries compare to transportation rival, FedEx (FDX 2.88%) to determine if UPS is better positioned to handle the vaccine rollout. Like UPS, FedEx has gained regulatory approval to deliver both the Pfizer/BioNTech and the Moderna vaccine. Both companies have expanded their healthcare logistics and services offerings over the past year. Ultimately, both shippers should benefit from the rollout, but UPS has some advantages over FedEx.

A health professional administers a COVID-19 vaccine to a lady.

Image source: Getty Images.

In late November, UPS beefed up its dry ice production capabilities and announced a partnership with Stirling Ultracold to make portable ultra-low temperature freezers. The ramp-up comes in addition to UPS' global network of re-icing stations. FedEx transports around half a million dry ice shipments every month, but UPS expects a dry ice shortage as pharmaceutical companies buy up dry ice to successfully conduct their vaccine rollouts. 

In addition to making its own dry ice, UPS has one of the most sophisticated international global biopharma networks. It can ship small to large freight shipments at cold to cryogenic temperatures across the world. UPS offers temperature monitoring that helps keep products within a safe temperature range. UPS sensors are able to log logistics and pinpoint when healthcare shipments will arrive. 

In addition to having a larger network, UPS' biggest advantage in the vaccine rollout is UPS Premier. Launched in May 2020, the precision logistics program is tailor-made for a vaccine rollout. According to a UPS statement:

This new technology-enabled for fee service is what we call a priority lane within the integrated UPS package network. We will be able to classify and identify critical healthcare shipments before they leave our customers' hands and enable greater visibility and control through their journey with technology. This is a major breakthrough in managing sensitive shipments that require an extra level of control.

Simply put, UPS is incredibly well-positioned to take advantage of the COVID-19 vaccine rollout. Investors should monitor logistics revenue, spending, and operating income to track how the vaccine distribution affects UPS's overall performance. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

United Parcel Service, Inc. Stock Quote
United Parcel Service, Inc.
$181.24 (1.60%) $2.86
FedEx Corporation Stock Quote
FedEx Corporation
$218.41 (2.88%) $6.12

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.